Clinical trials: Malignant Skin Tumor
NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Trial name
- PBC102 (NCT07250386)
- Testing
- CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
EXERCISING TOGETHER for Couples Coping With Cancer
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT03630354
- Testing
- Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention
- Where
- United States
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Melanoma (Skin), Melanoma
Head and Neck Melanoma; Access to Staging and Surgical Treatment
Melanoma is a serious type of skin cancer and is the 5th most common cancer in the United Kingdom (UK). It can affect anywhere on the skin including on the head and neck. The cancer often is first noticed as an abnormal mole.
- Trial name
- NCT05900102
- Where
- United Kingdom
- Volunteers
- 86,000 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Mastectomy, Lymphadenectomy
Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy
You should know that your participation in this study is voluntary and that you may decide NOT to participate. If you decide to participate, you may change your decision and withdraw your consent at any time, without altering…
- Conditions
- Mastectomy, Lymphadenectomy, Breast Neoplasm Malignant Female, Breast Surgery
- Trial name
- NCT06824831
- Testing
- Patients receive microporous polysaccharide hemospheres., Patients DO NOT receive microporous polysaccharide hemospheres.
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Stage IV Melanoma, Stage III Melanoma
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00019890
- Testing
- dendritic cell-gp100-MART-1 antigen vaccine, sargramostim
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05372640
- Testing
- Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasm of Breast
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Options for the treatment of patients who have progressed after an anthracycline and a taxane are limited. Capecitabine currently has a role in this setting, yet as many as 80% of patients do not respond to this treatment and…
- Trial name
- NCT01953003
- Testing
- vinflunine, Capecitabine
- Where
- 18 sites in China, Singapore and 1 more
- Volunteers
- 112 people
- Sponsor
- Pierre Fabre Medicament
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
This clinical trial tests the effectiveness of an interactive time-restricted diet intervention (txt4fasting) in reducing neurocognitive decline and improving survival outcomes after stereotactic radiosurgery in patients with…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT06315296
- Testing
- Behavioral Dietary Intervention, Text Message-Based Navigation Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Jefferson University
Melanoma
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This research study involves the use of two investigational drugs: sorafenib and bortezomib. Sorafenib is designed to stop the growth of cells caused by changes associated with cancer.
- Trial name
- NCT01078961
- Testing
- bortezomib, sorafenib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Malignant Melanoma, Metastatic
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
The study is an open-label, single arm single Center Phase II study to evaluate the safety and efficacy of the combination of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF, Leukine) and Ipilimumab (Yervoy) as therapy…
- Trial name
- GIPI (NCT01363206)
- Testing
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lynn E. Spitler, MD
Lung Cancer, Lung Infection
UNC Pleural Fluid Registry
Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat…
- Conditions
- Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion
- Trial name
- NCT05620329
- Where
- United States
- Volunteers
- 9,999 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphedema of Leg, Cancer of Cervix
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
The aim of the study is to explore the feasibility and safety of High Intensity Interval Training on a stationary bike for patients with lymphedema in the lower limbs and the role of compression garments during exercise.
- Conditions
- Lymphedema of Leg, Cancer of Cervix, Cancer, Ovarian, Cancer, Endometrial
- Trial name
- NCT03653819
- Testing
- First exercise session + compression, First exercise session - compression
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Herlev and Gentofte Hospital
Cutaneous Melanoma, Stage II
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe.
- Trial name
- MelMarT-II (NCT03860883)
- Testing
- Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
- Where
- 192 sites in United States, Australia and 8 more
- Volunteers
- 2,998 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Breast Carcinoma
Cryotherapy for Breast Cancer Trial
The purpose of this study is to evaluate the clinical feasibility and safety of the ICESENSE3TM cryotherapy system for the ablation of small malignant invasive breast tumors.
- Trial name
- ICE-BREACCER (NCT01671943)
- Testing
- Ice-Sense3TM
- Where
- Czechia
- Volunteers
- 4 people
- Sponsor
- IceCure Medical Ltd.
Malignant Melanoma
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
The primary objective of this pilot study is to assess the feasibility of mobilizing PD-1+ T cells to the peripheral blood after a single treatment with tremelimumab/durvalumab in patients with treatment naïve metastatic melanoma.
- Trial name
- NCT04223648
- Testing
- tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
- Sponsor
- Yale University
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Malignant Melanoma
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
- Trial name
- NCT00135408
- Testing
- Ipilimumab+ Budesonide
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.